当前位置:首页 - 行情中心 - 华森制药(002907) - 财务分析 - 利润表

华森制药

(002907)

  

流通市值:43.31亿  总市值:58.55亿
流通股本:3.09亿   总股本:4.18亿

利润表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、营业总收入515,257,554.58360,455,416.63187,539,020.46785,182,813.58
营业收入515,257,554.58360,455,416.63187,539,020.46785,182,813.58
二、营业总成本467,711,274.31317,792,881.58151,822,163.07685,929,256.31
营业成本222,654,037.36154,448,892.2874,438,227.92319,291,872.42
税金及附加7,104,821.875,441,599.581,781,182.4912,344,726.88
销售费用157,757,827.64109,708,337.652,929,378.1245,934,944.93
管理费用37,168,323.7324,454,577.7211,650,036.9746,590,650.12
研发费用49,402,354.928,914,218.3614,151,767.5958,820,972.09
财务费用-6,376,091.19-5,174,743.96-3,128,4302,946,089.87
其中:利息费用916,908.42637,784.38169,531.914,415,075.58
其中:利息收入7,338,713.85,842,236.63,312,105.6911,496,458.74
加:公允价值变动收益---1,518,648.22
加:投资收益-5,339,465.57-3,076,796.81-1,730,411.53-4,124,483.21
资产处置收益58,474.6858,474.6858,474.68-
资产减值损失(新)-868,259.43-383,192.97-276,738.27-1,260,752.64
信用减值损失(新)1,645,786.781,642,495.38377,771.13-3,348,412.56
其他收益8,652,056.356,240,449.041,600,680.2416,791,689.96
营业利润平衡项目0000
四、营业利润51,694,873.0847,143,964.3735,746,633.64108,830,247.04
加:营业外收入132,429.4466,721.1334,324.24202,754.53
减:营业外支出311,530.4810,037.785,037.78791,910.29
利润总额平衡项目0000
五、利润总额51,515,772.0447,200,647.7235,775,920.1108,241,091.28
减:所得税费用6,740,765.275,838,527.985,675,378.219,840,455.42
六、净利润44,775,006.7741,362,119.7430,100,541.8998,400,635.86
持续经营净利润44,775,006.7741,362,119.7430,100,541.8998,400,635.86
归属于母公司股东的净利润44,775,006.7741,362,119.7430,100,541.8998,400,635.86
(一)基本每股收益0.110.10.070.24
(二)稀释每股收益0.110.10.070.24
八、其他综合收益651,711.7762,330.62-55,429.94351,733.68
归属于母公司股东的其他综合收益651,711.7762,330.62-55,429.94351,733.68
九、综合收益总额45,426,718.4742,124,450.3630,045,111.9598,752,369.54
归属于母公司股东的综合收益总额45,426,718.4742,124,450.3630,045,111.9598,752,369.54
公告日期2023-10-272023-08-222023-04-282023-04-28
审计意见(境内)标准无保留意见
TOP↑